(4-butyl-2-methylphenyl)(methyl)amine | 398144-10-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-butyl-2-methylphenyl)(methyl)amine
• 英文别名: 4-butyl-N,2-dimethylaniline
• CAS: 398144-10-0
• 化学式: C₁₂H₁₉N
• 分子量: 177.29
• InChiKey: PTCHAGSENXLANE-UHFFFAOYSA-N

物化性质

• 沸点：
  274.8±19.0 °C(Predicted)
• 密度：
  0.928±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N,N-二甲基甲酰胺 、 (4-butyl-2-methylphenyl)(methyl)amine 在 氯化亚砜 、 盐酸羟胺 作用下， 以 甲醇 为溶剂， 以33%的产率得到N-(4-butyl-2-methylphenyl)-N'-hydroxy-N-methylmethanimidamide
  参考文献：
  名称：

  Discovery of a N′-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor

  摘要：

  N-(4-Butyl-2-methylphenyl)-N'-hydroxyformamidine (HET0016) was evaluated as the first potent and selective inhibitor of 20-hydroxy-5,8,11,14-eicosatetraenoic acid (20-HETE) synthase. The IC50 value of HET0016 for the production of 20-HETE from arachidonic acid (AA) by human renal microsomes was 8.9 +/- 2.7 nM, with over 200 times the selectivity of xenobiotic-metabolizing cytochrome P450 enzymes. An examination of the structure-activity relationship revealed that the unsubstituted hydroxyformamidine moiety and the substituent at the para-position of the N-hydroxyformamidine moiety are necessary for the potent activity of HET0016. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00614-x
• 作为产物：
  描述：

  4-丁基-2-甲基苯胺 在 sodium hydroxide 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 生成 (4-butyl-2-methylphenyl)(methyl)amine
  参考文献：
  名称：

  Discovery of a N′-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor

  摘要：

  N-(4-Butyl-2-methylphenyl)-N'-hydroxyformamidine (HET0016) was evaluated as the first potent and selective inhibitor of 20-hydroxy-5,8,11,14-eicosatetraenoic acid (20-HETE) synthase. The IC50 value of HET0016 for the production of 20-HETE from arachidonic acid (AA) by human renal microsomes was 8.9 +/- 2.7 nM, with over 200 times the selectivity of xenobiotic-metabolizing cytochrome P450 enzymes. An examination of the structure-activity relationship revealed that the unsubstituted hydroxyformamidine moiety and the substituent at the para-position of the N-hydroxyformamidine moiety are necessary for the potent activity of HET0016. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00614-x

文献信息

• [EN] MITOCHONDRIAL COMPLEX I INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS DU COMPLEXE MITOCHONDRIAL I ET MÉTHODES D'UTILISATION
  申请人：SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST

  公开号：WO2021050547A1

  公开（公告）日：2021-03-18

  Disclosed herein are methods of using mitochondrial complex I inhibitors in the treatment of a disease or condition that would benefit from the inhibition of mitochondrial respiration. Also described herein are methods of treating a disease or condition such as prostate cancer and breast cancer by administering a mitochondrial complex I inhibitor in combination with a second therapeutic agent.

  本文披露了使用线粒体复合物I抑制剂治疗需要抑制线粒体呼吸的疾病或状况的方法。本文还描述了通过联合使用线粒体复合物I抑制剂和第二治疗剂来治疗前列腺癌和乳腺癌等疾病或状况的方法。